Chandrakant Panchal

Rodocanachi Capital, Inc. operates as a capital pool company. The company was founded in March 5, 2008 and is headquartered in Montreal, Canada.

A.C. Simmonds & Sons, Inc. engages in identifying opportunities prime for consolidation, expansion and further development. It is focused on acquiring businesses for expansion and development food, manufacturing, transportation, mold remediation, oil and gas, and leisure and recreation industries. The company was founded in 1918 and is headquartered in King City, Canada.

CardioGenics, Inc. manufactures biotechnology and medical devices. It develops in-vitro-diagnostics cardiac testing products. The company was founded in 1997 and is headquartered in Mississauga, Canada.

Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

Axcelon Biopolymers Corp. provides medical devices for human health applications. It provides devices to those companies which uses nanotechnology to biodegradable polymer design and applications. Its technology includes stent coating, ophthalmology, drug delivery and regenerative medicine. The company is headquartered in Toronto, Canada

Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA.

Atlantic Coastal Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 7, 2020 and is headquartered in New York, NY.

Panacea Global, Inc. is a biotechnology company focused on the discovering, developing and commercializing of diagnostic products for the management of cancer. The company provides blood, serum and tissue tests to diagnose and monitor cancer through a licensing agreement with Panacea Pharmaceuticals. Its current product line allows for accurate detection of the most common forms of cancer, which includes diagnostic tests for lung, breast, prostate and colon cancers. The company was founded in 1995 and is headquartered in Richmond Hill, Canada.